MX2019004179A - Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. - Google Patents

Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2019004179A
MX2019004179A MX2019004179A MX2019004179A MX2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A
Authority
MX
Mexico
Prior art keywords
methods
disease
alzheimer
treatment
same
Prior art date
Application number
MX2019004179A
Other languages
English (en)
Inventor
Lichenstein Henri
M Rothberg Jonathan
Conrad Chris
HERNANDEZ Marylens
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of MX2019004179A publication Critical patent/MX2019004179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se relaciona con un método para tratar la enfermedad de Alzheimer con Apilimod y las composiciones y métodos relacionados.
MX2019004179A 2016-10-12 2017-10-11 Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. MX2019004179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407186P 2016-10-12 2016-10-12
PCT/US2017/056147 WO2018071548A1 (en) 2016-10-12 2017-10-11 Apilimod compositions and methods for using same in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2019004179A true MX2019004179A (es) 2019-09-02

Family

ID=60268450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004179A MX2019004179A (es) 2016-10-12 2017-10-11 Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.

Country Status (12)

Country Link
US (1) US20190365771A1 (es)
EP (1) EP3525794A1 (es)
JP (1) JP7199349B2 (es)
KR (1) KR20190067824A (es)
CN (1) CN110167559A (es)
AU (1) AU2017342262B2 (es)
BR (1) BR112019007214A2 (es)
CA (1) CA3039199A1 (es)
IL (1) IL265911A (es)
MX (1) MX2019004179A (es)
RU (1) RU2019113752A (es)
WO (1) WO2018071548A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008680A (es) 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630363A (en) 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AU2012204869B2 (en) * 2011-01-04 2016-01-28 Charite Universitatsmedizin Berlin Modulators of IL-12 and/or IL-23 for the prevention or treatment of Alzheimer's disease
EP3215158B1 (en) * 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20190209576A1 (en) * 2014-11-07 2019-07-11 AI Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
US10729694B2 (en) * 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
US20180015098A1 (en) * 2015-02-03 2018-01-18 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016210372A2 (en) * 2015-06-25 2016-12-29 University Of Southern California Methods to treat neurological diseases

Also Published As

Publication number Publication date
BR112019007214A2 (pt) 2019-07-02
IL265911A (en) 2019-06-30
CN110167559A (zh) 2019-08-23
CA3039199A1 (en) 2018-04-19
JP7199349B2 (ja) 2023-01-05
US20190365771A1 (en) 2019-12-05
JP2019530711A (ja) 2019-10-24
RU2019113752A (ru) 2020-11-13
AU2017342262B2 (en) 2023-09-28
WO2018071548A1 (en) 2018-04-19
AU2017342262A1 (en) 2019-04-18
KR20190067824A (ko) 2019-06-17
EP3525794A1 (en) 2019-08-21
RU2019113752A3 (es) 2021-01-19

Similar Documents

Publication Publication Date Title
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
TW201613636A (en) Methods of treating Alzheimer's Disease
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
ZA202002779B (en) Dantrolene prodrugs and methods of their use
PH12018501443A1 (en) Methods of administering hepcidin
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2019000677A (es) Células miméticas de células b.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
PH12019501358A1 (en) Methods of administering hepcidin
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EP3628008A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci